Orange Book product · Generic (ANDA)
ISOSULFAN BLUE
ISOSULFAN BLUE
At a glance
May 17, 2023
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 17, 2023
3 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
ISOSULFAN BLUE
Strength
50MG/5ML (10MG/ML)
Dosage form
SOLUTION
Route
SUBCUTANEOUS
TE code
AP
Application
ANDA 210294
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ISOSULFAN BLUE
- —LYMPHAZURINBrand (NDA)
NDA 018310 · COVIDIEN
- 2026ISOSULFAN BLUEGeneric (ANDA)
ANDA 090874 · MYLAN INSTITUTIONAL
- 2022ISOSULFAN BLUEGeneric (ANDA)
ANDA 216090 · MSN
- 2022ISOSULFAN BLUEGeneric (ANDA)
ANDA 211869 · FRESENIUS KABI USA
- 2021ISOSULFAN BLUEGeneric (ANDA)
ANDA 213130 · MEITHEAL
- 2019ISOSULFAN BLUEGeneric (ANDA)
ANDA 210558 · SOMERSET THERAPS LLC
- 2019ISOSULFAN BLUEGeneric (ANDA)
ANDA 210714 · SABA ILAY SANAYI
- 2016ISOSULFAN BLUEGeneric (ANDA)
ANDA 206831 · EUGIA PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
